Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for IDE849 (SHR-4849) in Solid tumors. The expected timing is based on the latest available company guidance and may change.
Licensed from Jiangsu Hengrui. 5/6/25- FDA IND-clearance to initiate Ph1 trial in the US. 9/8/25- Present Ph1 data at IASLC 2025. 11/04/25:- WCLC Ph1 SCLC data show high ORR; global trial enrolling, US FPI achieved; NET/DLL3 tumor expansion planned YE 2025. 02/17/26:- Preliminary global Phase 1 IDE849 data and initiation of 2L+ SCLC/NEC monotherapy registrational study targeted by YE 2026. 03/30/26:- Ph1 IDE849 multiple PRs; registrational study planned YE 2026; monotherapy and IDE161 combo data update H2 2026. 05/05/26:- Targeting global IDE849 Ph1/2 data update and monotherapy registrational trial YE 2026; added Imfinzi combo and China Ph3 2027. 07/17/26:- China Ph1 long-term results to be presented at ESMO Oct 23-27, 2026. Registrational trial targeted YE 2026. 08/04/26:- IDE849 ESMO data planned October 2026; global data H2 2026; registrational start YE 2026.
Verification
Confirm timing and program details against the company announcement or filing.